Egetis Therapeutics AB (publ)
Research Egetis Therapeutics AB (publ) (EGTX) on Bullrun: market cap SEK 3.41B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEGTX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 3.41B
- Financial periodQ1 2026
- RevenueSEK 13.40M
- Net income-SEK 94.50M
- Free cash flow-SEK 64.30M
- Gross margin-1.5%
Valuation Snapshot
latest market cap is SEK 3.41B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 62.50M | -SEK 342.60M | -SEK 268.70M | 19.8% | -0.9 | SEK 215.80M | SEK 90.60M | SEK 338.60M |
| FY2024 | SEK 46.10M | -SEK 343.60M | -SEK 227.90M | 74.8% | -1.1 | SEK 351.00M | SEK 84.10M | SEK 492.90M |
| FY2023 | SEK 57.60M | -SEK 326.90M | -SEK 278.40M | 80.9% | -1.3 | SEK 303.30M | SEK 103.40M | SEK 545.60M |
| FY2022 | SEK 22.60M | -SEK 193.80M | -SEK 173.50M | 72.1% | -1 | SEK 127.70M | SEK 0 | SEK 506.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 3.41B | n/a | n/a | n/a |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Egetis Therapeutics AB (publ)'s market cap?
Egetis Therapeutics AB (publ)'s market capitalization is SEK 3.41B.
What does Egetis Therapeutics AB (publ) do?
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.